Semaglutide faces renewed legal battles as Novo Nordisk targets compounding pharmacies for trademark infringement and false advertising after FDA shortage removal.
Armin Ghiam
Advertisement
Armin Ghiam is a partner in Hunton Andrews Kurth LLP’s Intellectual Property group in the firm’s New York office. With an international background in law, finance and technology, he counsels clients on litigation, prosecution and transactions involving patents, trademarks, copyrights and trade secrets.
Articles by Armin Ghiam
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Medical Economics
1
Dexcom Smart Basal wins FDA Clearance for Type 2 diabetes insulin support
2
Former nursing home CEO sentenced in $146M fraud scheme; AI in the ICU; cannabis in pregnancy – Morning Medical Update
3
Executives guilty in $100M Adderall scheme; California sober; training viruses to fight superbugs – Morning Medical Update
4
U.S. leads in primary care physician burnout among 10 developed nations, study says
5
